Table 4.

Rectal cancer pooled analysis: 5-year relapse rates by treatment method for intermediate-risk, moderately high-risk, and high-risk patients.

Risk group/TN stage	S + CT(%)	RT + bolus CT*(%)	RT + PVI CT(%)	RT + bolus CT†(%)
Local relapse
Intermediate risk
T1-2N1 (n = 355)	5	6	5	6
T3N0 (n = 1,058)	11	10	5	8
Moderately high risk
T1-2N2 (n = 226)	0	13	11	9
T3N1 (n = 881)	17	12	9	10
T4N0 (n = 111)	20 (10)‡	18	10	11
High risk
T3N2 (n = 929)	15	17	11	15
T4N1 (n = 62)	43 (7)‡	0	18	22
T4N2 (n = 108)	0 (4)	22	33	16
Distant relapse
Intermediate risk
T1-2N1 (n = 355)	16	14	15	14
T3N0 (n = 1,058)	18	20	13	18
Moderately high risk
T1-2N2 (n = 226)	57	40	61	28
T3N1 (n = 881)	37	35	30	33
T4N0 (n = 111)	20 (10)‡	27	59	25
High risk
T3N2 (n = 929)	46	53	30	41
T4N1 (n = 62)	43 (7)‡	40	36	34
T4N2 (n = 108)	75 (4)‡	78	22	53

Modified from Gunderson et al¹²

^*NCCTG and NSABP trials

^†INT 0114

^‡Number of patients at risk

Abbreviations: CT = chemotherapy; NCCTG = North Central Cancer Treatment Group; NSABP = National Surgical Adjuvant Breast and Bowel Project; PVI = protracted venous infusion; RT = radiotherapy; S = surgery; TN = N substage within T stage